Friday, 13 Jul 2018

You are here

Epigenetic Link in Rheumatoid Arthritis to Huntington's Disease

Researchers at University of California San Diego School and the Icahn School of Medicine have found a high-resolution epigenomic landscape of rheumatoid arthritis (RA) that overlaps with that seen in Huntington's disease, suggesting potentially new unanticipated pathways that could be developed into therapeutic targets.

Their study, published in Nature Communications, presented a comprehensive epigenomic characterization of RA fibroblast-like synoviocytes and their epigenetic changes and found that epigenomically similar regions exist in RA cells that are associated with active enhancers and promoters and specific transcription factor binding motifs. Surprisingly these were similar to that seen in Huntington’s Disease, a fatal and incurable genetic brain disease. 

The investigators studied the epigenome using cells from RA joints to identifiy unique epigenetic changes. Analysis of chromatin, DNA methylation, RNA expression and histone modifications resulted in large amounts of data that were algorithmically managed to reduced the number of epigenetic combinations in the genes of patients with RA. The purpose of which was to new cell signaling pathways utilized in RA.

Epigenetics is the study of alterations in gene structure without necessarily changing the DNA sequence itself. Epigenetics have become increasingly important in understanding many disorders, as epigenetic changes can be influenced by a variety of environmental factors, including aging, activity and lifestyle choices.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The Diverse Fate of Seronegative Rheumatoid Arthritis

A Finnish Rheumatology Center followed 435 early, seronegative rheumatoid arthritis (RA) patients for 10-years and found that only 3% became erosive or seropositive RA. They also found that 32% could not be further reclassified, and that the remaining 65% evolve into another diagnosis, led by polymyalgia rheumatica (16%), psoriatic arthritis (11%), spondyloarthritis (9%), and osteoarthritis (10%).  

Does RA Have a Prodrome?

A pattern of increased primary care visits and joint complaints during the 2 years before rheumatoid arthritis (RA) was diagnosed were predictive of the diagnosis, a British case-control study found.

Can DMARDs Delay Rheumatoid Onset?

Preclinical rheumatoid arthritis (RA) is a hot new area wherein at risk individuals (seropositive, first degree relatives of RA patients, etc.) are being studied to assess the triggers that lead to progression to RA or whether therapies can be used to avert the onset of RA.

Seronegative and Seropositive Rheumatoids Respond Equally Well

A cohort study of 241 DMARD-naive rheumatoid arthritis (RA) patients, meeting either 1987 ACR or the 2010 ACR/EULAR  classification criteria for RA, compared the baseline status and long term outcomes of seronegative (SNRA) and seropositive (SPRA).

We Measure What we do in RA, But so What?

We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change.